SELLAS Life Sciences Group, Inc. (SLS) financial statements (2020 and earlier)
Company profile
| Business Address |
15 WEST 38TH STREET NEW YORK, NY 10018 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 7 | 5 | 2 | 18 | 30 | ||
| Cash and cash equivalents | 7 | 5 | 2 | 18 | 30 | ||
| Restricted cash and investments | 0 | 0 | 10 | 18 | 0 | ||
| Receivables | 22 | ||||||
| Prepaid expense | 0 | ||||||
| Disposal group, including discontinued operation | 1 | 0 | |||||
| Other undisclosed current assets | 1 | 0 | 0 | 1 | 1 | ||
| Total current assets: | 8 | 6 | 13 | 37 | 54 | ||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 0 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 0 | 0 | |||||
| Intangible assets, net (including goodwill) | 2 | 2 | 20 | 6 | 6 | ||
| Goodwill | 2 | 2 | 2 | 6 | 6 | ||
| Intangible assets, net (excluding goodwill) | 18 | ||||||
| Regulated entity, other noncurrent assets | (0) | ||||||
| Deposits noncurrent assets | 1 | 1 | 1 | 0 | 0 | ||
| Deferred tax assets, net | ✕ | (6) | (5) | ||||
| Other undisclosed noncurrent assets | 6 | 9 | 28 | 28 | |||
| Total noncurrent assets: | 8 | 11 | 20 | 28 | 29 | ||
| TOTAL ASSETS: | 17 | 17 | 34 | 66 | 82 | ||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 5 | 6 | 15 | 5 | 7 | ||
| Accounts payable | 4 | 4 | 12 | 1 | 2 | ||
| Accrued liabilities | 1 | 2 | 3 | 4 | 5 | ||
| Debt | 0 | 8 | 16 | 5 | |||
| Estimated litigation liability | 1 | 1 | 25 | ||||
| Disposal group, including discontinued operation | 6 | 6 | |||||
| Other undisclosed current liabilities | 2 | 15 | |||||
| Total current liabilities: | 5 | 6 | 25 | 30 | 57 | ||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 3 | ||||||
| Long-term debt, excluding current maturities | 3 | ||||||
| Liabilities, other than long-term debt | 0 | 2 | |||||
| Deferred tax liabilities, net | ✕ | 2 | |||||
| Deferred income tax liabilities | 0 | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed noncurrent liabilities | 5 | 6 | 3 | 7 | 12 | ||
| Total noncurrent liabilities: | 5 | 6 | 7 | 7 | 12 | ||
| Total liabilities: | 11 | 12 | 31 | 37 | 69 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | 6 | 5 | 2 | 29 | 14 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (4) | (4) | |||||
| Additional paid in capital | 107 | 87 | 56 | 335 | 297 | ||
| Accumulated deficit | (101) | (82) | (54) | ||||
| Other undisclosed stockholders' equity attributable to parent | (303) | (279) | |||||
| Total stockholders' equity: | 6 | 5 | 2 | 29 | 14 | ||
| TOTAL LIABILITIES AND EQUITY: | 17 | 17 | 34 | 66 | 82 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|
| Cost of goods and services sold | (5) | |||||
| Gross profit: | (20) | (31) | (5) | |||
| Operating expenses | (23) | (32) | (34) | |||
| Other undisclosed operating income | 5 | |||||
| Operating loss: | (20) | (31) | (23) | (32) | (34) | |
| Nonoperating income (expense) | (19) | (29) | 21 | (4) | ||
| Other nonoperating income | 5 | 1 | ||||
| Interest and debt expense | 1 | 3 | ||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (3) | |||||
| Loss from continuing operations before equity method investments, income taxes: | (39) | (59) | (23) | (11) | (39) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 20 | 30 | (0) | |||
| Loss from continuing operations before income taxes: | (19) | (29) | (24) | (11) | (39) | |
| Income tax expense (benefit) | 0 | 1 | (0) | (0) | (0) | |
| Other undisclosed loss from continuing operations | (0) | |||||
| Net loss: | (19) | (28) | (24) | (11) | (39) | |
| Other undisclosed net loss attributable to parent | (12) | (25) | ||||
| Net loss attributable to parent: | (19) | (28) | (24) | (24) | (64) | |
| Preferred stock dividends and other adjustments | (4) | |||||
| Other undisclosed net loss available to common stockholders, basic | (9) | (9) | (1) | |||
| Net loss available to common stockholders, diluted: | (28) | (41) | (24) | (24) | (64) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|
| Net loss: | (19) | (28) | (24) | (11) | (39) | |
| Other comprehensive loss | (64) | |||||
| Comprehensive loss, net of tax, attributable to parent: | (19) | (28) | (24) | (11) | (103) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.